Mast cells' involvement in inflammation pathways linked to depression: Evidence in mastocytosis

Molecular Psychiatry

Volumn 21, Issue 11, 2016, Pages 1511-1516

  Georgin Lavialle, S ^a,b,c   Moura, D S ^a,b   Salvador, A ^d,e   Chauvet Gelinier, J C ^f,g   Launay, J M ^h   Damaj, G ⁱ   Cote F ^f   Soucie E ^d   Chandesris, M O ^a   Barete S ^a,b   Grandpeix Guyodo, C ^a   Bachmeyer, C ^c   Alyanakian, M A ^b   Aouba, A ^a   Lortholary, O ^a   Dubreuil, P ^a,d   Teyssier, J R ^j   Trojak, B ^e,f   Haffen, E ^j,k,l   Vandel, P ^k,l   Bonin, B ^f,g   Hermine, O ^a,b   Gaillard, R ^a,d,e,m   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

^e CENTRE HOSPITALIER SAINTE ANNE   (France)

^f Service de Psychiatrie   (France)

^g UNIVERSITÉ DE BOURGOGNE   (France)

^h HÔPITAL LARIBOISIÈRE   (France)

ⁱ AMIENS UNIVERSITY HOSPITAL   (France)

^j DIJON UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF BESANÇON   (France)

^l University Hospital of Besançon   (France)

^m INSTITUT PASTEUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; KYNURENINE; QUINOLINIC ACID; SEROTONIN 5 RECEPTOR; TRYPTOPHAN; SEROTONIN;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CATABOLISM; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; ENZYME ACTIVATION; FEMALE; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; MAST CELL; MASTOCYTOSIS; MIDDLE AGED; PERCEIVED STRESS SCALE; PRIORITY JOURNAL; MAJOR DEPRESSION; MENTAL STRESS; METABOLISM; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE;

DEPRESSION; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; KYNURENIC ACID; KYNURENINE; MALE; MAST CELLS; MASTOCYTOSIS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; STRESS, PSYCHOLOGICAL; TRYPTOPHAN;

EID: 84992195351     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.216     Document Type: Article

References (79)

1. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsycho-pharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2012; 37: 137-162.
2. Dantzer R, Heijnen CJ, Kavelaars A, Laye S, Capuron L. The neuroimmune basis of fatigue. Trends Neurosci 2014; 37: 39-46.
3. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharma-cological implications. Pharmacol Ther 2011; 130: 226-238.
4. Maes M, Berk M, Goehler L, Song C, Anderson G, Gałecki P et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012; 10: 66.
5. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
6. Miller AH. Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 2009; 23: 149-158.
7. Hoyo-Becerra C, Schlaak JF, Hermann DM. Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation. Brain Behav Immun 2014; 42C: 222-231.
8. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 664-675.
9. Kreisel T, Frank MG, Licht T, Reshef R, Ben-Menachem-Zidon O, Baratta MV et al. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry 2014; 19: 699-709.
10. Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci 2014; 15: 300-312.
11. Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners in crime? Immunology 2014; 141: 314-327.
12. Silver R, Curley JP. Mast cells on the mind: new insights and opportunities. Trends Neurosci 2013; 36: 513-521.
13. Nelissen S, Lemmens E, Geurts N, Kramer P, Maurer M, Hendriks J et al. The role of mast cells in neuroinflammation. Acta Neuropathol (Berl) 2013; 125: 637-650.
14. Frenzel L, Hermine O. Mast cells and inflammation. Jt Bone Spine Rev Rhum 2013; 80: 141-145.
15. Skaper SD, Facci L, Giusti P. Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review. CNS Neurol Disord Drug Targets 2014; 13: 1654-1666.
16. Nautiyal KM, Ribeiro AC, Pfaff DW, Silver R. Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci USA 2008; 105: 18053-18057.
17. Carter MC, Metcalfe DD, Komarow HD. Mastocytosis. Immunol Allergy Clin North Am 2014; 34: 181-196.
18. Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin North Am 2014; 34: 207-218.
19. Moura DS, Georgin-Lavialle S, Gaillard R, Hermine O. Neuropsychological features of adult mastocytosis. Immunol Allergy Clin North Am 2014; 34: 407-422.
20. Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P et al. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PloS One 2011; 6: e26375.
21. Moura DS, Sultan S, Georgin-Lavialle S, Barete S, Lortholary O, Gaillard R et al. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PloS One 2012; 7: e39468.
22. Rogers MP, Bloomingdale K, Murawski BJ, Soter NA, Reich P, Austen KF. Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom Med 1986; 48: 437-447.
23. Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C et al. Case-control cohort study of patients' perceptions of disability in mastocytosis. PloS One 2008; 3: e2266.
24. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryp-tophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538-544.
25. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010; 15: 393-403.
26. Myint A-M, Schwarz MJ, Müller N. The role of the kynurenine metabolism in major depression. J Neural Transm 2012; 119: 245-251.
27. Georgin-Lavialle S, Lhermitte L, Baude C, Barete S, Bruneau J, Launay J-M et al. Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic masto-cytosis and behaves like a mast cell precursor. Blood 2011; 118: 5246-5249.
28. Beck A, Steer R, Brown G. Beck Depression Inventory. The Psychological Corporation: San Antonio, TX, 1996.
29. Aben I, Verhey F, Lousberg R, Lodder J, Honig A. Validity of the Beck Depression Inventory, Hospital Anxiety and Depression Scale, SCL-90, and Hamilton Depression Rating Scale as screening instruments for depression in stroke patients. Psychosomatics 2002; 43: 386-393.
30. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983; 24: 385-396.
31. Kema IP, Schellings AM, Hoppenbrouwers CJ, Rutgers HM, de Vries EG, Muskiet FA. High performance liquid chromatographic profiling of tryptophan and related indoles in body fluids and tissues of carcinoid patients. Clin Chim Acta Int J Clin Chem 1993; 221: 143-158.
32. Fujigaki S, Saito K, Takemura M, Fujii H, Wada H, Noma A et al. Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes. Arch Biochem Biophys 1998; 358: 329-335.
33. Swartz KJ, During MJ, Freese A, Beal MF. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci Off J Soc Neurosci 1990; 10: 2965-2973.
34. Heyes MP, Markey SP. Quantification of quinolinic acid in rat brain, whole blood, and plasma by gas chromatography and negative chemical ionization mass spectrometry: effects of systemic L-tryptophan administration on brain and blood quinolinic acid concentrations. Anal Biochem 1988; 174: 349-359.
35. Pagan C, Delorme R, Callebert J, Goubran-Botros H, Amsellem F, Drouot X et al. The serotonin-N-acetylserotonin-melatonin pathway as a biomarker for autism spectrum disorders. Transl Psychiatry 2014; 4: e479.
36. Stiegel MA, Pleil JD, Sobus JR, Morgan MK, Madden MC. Analysis of inflammatory cytokines in human blood, breath condensate, and urine using a multiplex immunoassay platform. Biomark Biochem Indic Expo Response Susceptibility Chem 2015; 20: 35-46.
37. Savitz J, Drevets WC, Smith CM, Victor TA, Wurfel BE, Bellgowan PS et al. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2015; 40: 463-471.
38. Schwarcz R, Bruno JP, Muchowski PJ, Wu H-Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-477.
39. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein H-G, Sarnyai Z et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 2011; 8: 94.
40. Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsycho-pharmacol Off Publ Am Coll Neuropsychopharmacol 2013; 38: 743-752.
41. Fox JM, Crabtree JM, Sage LK, Tompkins SM, Tripp RA. Interferon Lambda upre-gulates IDO1 expression in respiratory epithelial cells after influenza virus infection. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res 2015; 35: 554-562.
42. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-966.
43. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237-241.
44. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19: 105-123.
45. Capuron L, Fornwalt FB, Knight BT, Harvey PD, Ninan PT, Miller AH. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord 2009; 119: 181-185.
46. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 41-48.
47. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70: 31-41.
48. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 445-452.
49. Krabbe KS, Reichenberg A, Yirmiya R, Smed A, Pedersen BK, Bruunsgaard H. Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun 2005; 19: 453-460.
50. DellaGioia N, Hannestad J. A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci Biobehav Rev 2010; 34: 130-143.
51. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Dolan RJ et al. Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry 2009; 66: 415-422.
52. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new « 5-HT » hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxy-genase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 702-721.
53. Khalil M, Ronda J, Weintraub M, Jain K, Silver R, Silverman A-J. Brain mast cell relationship to neurovasculature during development. Brain Res 2007; 1171: 18-29.
54. Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the « brain-skin connection ». Trends Immunol 2006; 27: 32-39.
55. Campbell DJ, Kernan JA. Mast cells in the central nervous system. Nature 1966; 210: 756-757.
56. Cirulli F, Pistillo L, de Acetis L, Alleva E, Aloe L. Increased number of mast cells in the central nervous system of adult male mice following chronic subordination stress. Brain Behav Immun 1998; 12: 123-133.
57. Edvinsson L, Cervós-Navarro J, Larsson LI, Owman C, Rönnberg AL. Regional distribution of mast cells containing histamine, dopamine, or 5-hydroxytryptamine in the mammalian brain. Neurology 1977; 27: 878-883.
58. Esposito P, Gheorghe D, Kandere K, Pang X, Connolly R, Jacobson S et al. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001; 888: 117-127.
59. Theoharides TC. Mast cells and stress - a psychoneuroimmunological perspective. J Clin Psychopharmacol 2002; 22: 103-108.
60. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004; 146: 1-12.
61. Kawasaki H, Chang H-W, Tseng H-C, Hsu S-C, Yang S-J, Hung C-H et al. A tryp-tophan metabolite, kynurenine, promotes mast cell activation through aryl hydrocarbon receptor. Allergy 2014; 69: 445-452.
62. Zhou Y, Tung H-Y, Tsai Y-M, Hsu S-C, Chang H-W, Kawasaki H et al. Aryl hydrocarbon receptor controls murine mast cell homeostasis. Blood 2013; 121: 3195-3204.
63. Sibilano R, Frossi B, Calvaruso M, Danelli L, Betto E, Dall'Agnese A et al. The aryl hydrocarbon receptor modulates acute and late mast cell responses. J Immunol 2012; 189: 120-127.
64. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
65. Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007; 157: 1275-1277.
66. Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol Off J Am Soc Clin Oncol 2006; 24: 1852-1859.
67. Maes M, Song C, Yirmiya R. Targeting IL-1 in depression. Expert Opin Ther Targets 2012; 16: 1097-1112.
68. Maes M, Anderson G, Kubera M, Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets 2014; 18: 495-512.
69. Kushnir-Sukhov NM, Brittain E, Scott L, Metcalfe DD. Clinical correlates of blood serotonin levels in patients with mastocytosis. Eur J Clin Invest 2008; 38: 953-958.
70. Hannestad J, DellaGioia N, Ortiz N, Pittman B, Bhagwagar Z. Citalopram reduces endotoxin-induced fatigue. Brain Behav Immun 2011; 25: 256-259.
71. O'Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci Off J Soc Neurosc 2009; 29: 4200-4209.
72. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008; 222: 206-221.
73. Kox M, Pompe JC, Gordinou de Gouberville MC, van der Hoeven JG, Hoedemaekers CW, Pickkers P. Effects of the α7 nicotinic acetylcholine receptor agonist GTS-21 on the innate immune response in humans. Shock 2011; 36: 5-11.
74. Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009; 9: 418-428.
75. Schwarcz R, Whetsell WO Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983; 219: 316-318.
76. Aan Het Rot M, Zarate CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry 2012; 72: 537-547.
77. De Maricourt P, Jay T, Goncalvès P, Lôo H, Gaillard R. [Ketamine's antidepressant effect: literature review on clinical use]. L'Encéphale 2014; 40: 15-23.
78. Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2013; 38: 1609-1616.
79. Kocic I, Kowianski P, Rusiecka I, Lietzau G, Mansfield C, Moussy A et al. Neuro-protective effect of masitinib in rats with postischemic stroke. Naunyn Schmie-debergs Arch Pharmacol 2015; 388: 79-86.